Pharmaxis Ltd operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Pharmaxis Ltd with three other
companies in this sector in Australia:
Anteo Diagnostics Limited
sales of 12.67 million Australian Dollars [US$9.52 million]
Idt Australia Limited.
(16.91 million Australian Dollars [US$12.70 million]
of which 55%
was CMAX), and
Xrf Scientific Ltd
(21.13 million Australian Dollars [US$15.87 million]
of which 43%
was Precious Metals).
Sales fell dramatically in 2016:
During the year ended June of 2016, sales at
Pharmaxis Ltd were A$18.57 million (US$13.94 million).
decrease of 68.3%
versus 2015, when the company's sales were A$58.63 million.
Contributing to the drop in overall sales was the 93.6% decline
in New Drug Development, from A$40.60 million to A$2.58 million.
There were also decreases in sales in
Bronchitol and Aridol (down 15.0% to A$14.91 million)
Corporate (down 17.0% to A$317,000.00 )